Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer.
- Author:
Lin-Ping GU
1
;
Sheng-Ping SHEN
;
Zhi-Wei CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; adverse effects; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; Disease-Free Survival; Female; Humans; Leukopenia; chemically induced; Lung Neoplasms; drug therapy; pathology; Male; Middle Aged; Nausea; chemically induced; Neoplasm Staging; Neutropenia; chemically induced; Organoplatinum Compounds; administration & dosage; adverse effects; Retrospective Studies; Survival Rate; Taxoids; administration & dosage; adverse effects; therapeutic use; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2010;32(12):939-942
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the curative effect, safety and survival of Nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced NSCLC.
METHODSFrom Sep 2005 to Mar 2009, fifty-eight patients with NSCLC treated in the Shanghai Chest Hospital who failed first-line chemotherapy and receiving docetaxel or docetaxel combined with nedaplatin were retrospectively analyzed. Survival analysis was evaluated by Kaplan-Meier and Log-Rank test. There were 20 patients in the combination group, and 38 in the single-agent group.
RESULTSThe PFS was 4.35 months for combination group and 4.0 months for single-agent group, there was a significant difference between the two groups (P < 0.05). The mean survival time and 1-year survival rate were 13.5 months vs. 10.6 months and 29.0% vs. 22.0%, respectively, with no significant difference. The Hematological toxicity in the combination group was higher than that in the single-agent group, 15.0% vs. 10.5% (P = 0.003), and no renal toxicity was noted in this study.
CONCLUSIONSCompared with the treatment with docetaxel alone, Nedaplatin combined with docetaxel as a second line treatment for NSCLC has a better curative effect and acceptable toxicity.
